Efficacy and safety of peppermint oil for the treatment in Japanese patients with irritable bowel syndrome: a prospective, open-label, and single-arm study

Table 8 Change in stool frequency score for each IBS subtype score (FAS)

IBS subtypes	Visit	N	Change in stool frequency score					95% CI of mean	Paired t-tests
IBS subtypes	Visit	N	Mean	SD	Minimum	Median	Maximum	95% CI of mean	Paired t-tests
IBS-C	Week 2	18	0.21	0.34	-0.4	0.20	1.0	0.04, 0.37	p = 0.020
IBS-C	Week 4	18	0.17	0.30	-0.5	0.20	0.7	0.03, 0.32	p = 0.026
IBS-D	Week 2	33	-0.02	0.42	-1.1	0.00	0.7	-0.16, 0.13	p = 0.835
IBS-D	Week 4	33	0.09	0.57	-0.9	0.10	1.5	-0.10, 0.29	p = 0.350
IBS-M	Week 2	16	0.13	0.43	-0.9	0.25	0.9	-0.10, 0.36	p = 0.245
IBS-M	Week 4	16	0.04	0.42	-1.0	0.05	0.6	-0.18, 0.26	p = 0.725
Total	Week 2	67	0.08	0.41	-1.1	0.10	1.0	-0.02, 0.17	p = 0.117
Total	Week 4	67	0.10	0.47	-1.0	0.10	1.5	-0.01, 0.21	p = 0.083

Amount of change in stool frequency score = “frequency at 2, 4 weeks after treatment (or at the end of treatment)”– “frequency at baseline”
SD standard deviation

ISSN: 1751-0759